

## Special Issue

# Bacterial Vaccine: Mucosal Immunity and Implications

### Message from the Guest Editors

Although numerous effective mucosal vaccines are in use, the use of these vaccines has not yet been translated into licensed mucosal vaccines and this is due to its solely live attenuated and inactivated whole-cell preparations. Therefore, this Special Issue in *Vaccines* reflects the research interest of scientific communities involved in studying therapeutics or prophylactic interventions against bacterial pathogens, infecting via mucosal barriers. Additionally, the development of mucosal bacterial vaccines will offer a potential fortification at the mucosal site of entry. Publication of scientific studies or potential research work focusing on vaccine development, host-pathogen interaction, establishment of protection innate and adaptive immune factors, and their mechanism of cross-talk will be considered equally.

---

### Guest Editors

Dr. Amit K. Singh

Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA

Dr. Raj Kumar

Department of Physiology, The University of Tennessee Health Science Center, Memphis, TN 38163, USA

---

### Deadline for manuscript submissions

closed (30 September 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/132383](https://mdpi.com/si/132383)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).